Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Dupixent is the first and only biologic to achieve significant improvements in ...
Dupixent showed significant improvements in disease remission and symptoms in bullous pemphigoid, meeting primary and secondary endpoints, with five times more patients achieving remission compared to placebo. It's the first medicine to show a significant steroid-sparing effect and could be the first targeted treatment for BP in the U.S. and EU if approved.
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene announces the appointment of Dr. Emmanuelle Dochy as Chief Medical Officer and Dr. Maurizio Ceppi as Chief Scientific Officer to advance cancer immunotherapies and precision medicine. Both appointees bring extensive experience in oncology and clinical development. Dr. Dochy succeeds Dr. Maud Brandely, and Dr. Ceppi succeeds Eric Quéméneur, who are both retiring or pursuing other interests. The new leadership positions Transgene to deliver innovative treatments to cancer patients.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With ...
Vir Biotechnology closed a strategic agreement with Sanofi, gaining exclusive worldwide licenses to three clinical-stage masked T-cell engagers (TCEs) for cancer treatments and the PRO-XTEN masking platform for oncology and infectious disease. The TCEs include SAR446309 (HER2-targeted), SAR446329 (PSMA-targeted), and SAR446368 (EGFR-targeted), with clinical studies underway or planned. Key Sanofi employees with expertise in TCEs and the PRO-XTEN platform will join Vir.
Paris court revokes Sanofi cabazitaxel patent
The Judicial Court of Paris revoked Sanofi’s EP 2 493 466 patent on cabazitaxel due to obviousness, marking another setback in the dispute with generic drug companies over Jevtana. French judges consistently favor generics in pharmaceutical disputes. Sanofi’s second medical use patent for cabazitaxel, used in Jevtana, faces ongoing challenges from Teva, Accord Healthcare, and Ever Pharma. The EPO Technical Boards of Appeal will hear an appeal against the patent’s grant in April 2025, and UPC cases are pending.
Vir Biotechnology names new CFO to boost financial strategy
Vir Biotechnology Inc. appoints Jason O'Byrne as EVP and CFO, effective October 2, 2024. O'Byrne brings over two decades of financial and operational experience, including roles at Caribou Biosciences and Audentes Therapeutics. Vir focuses on infectious diseases and cancer treatments, with recent FDA approvals and a licensing deal with Sanofi. The company is restructuring, reducing workforce by 25%, and faces financial challenges despite holding more cash than debt.
New report investigates pharma's global reach and impact
A report by the Access to Medicine Foundation examines how 20 major pharmaceutical companies are addressing patient access in low- and middle-income countries (LMICs), highlighting progress and areas needing improvement. The report identifies 42 different approaches to measuring patient reach, with 19 companies actively tracking this, but no industry-wide consensus. It calls for clearer, more actionable commitments to ensure lifesaving products reach underserved populations, emphasizing the need for collaboration and refining measurement methods to address health inequities.
Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments
Vir Biotechnology finalized a global licensing deal with Sanofi for three clinical-stage T-cell engagers and a protease-cleavable masking platform, paying $100 million initially and potentially over $1.8 billion, plus royalties. The deal also transfers key Sanofi employees to Vir. Vir appointed Jason O’Byrne as CFO and Brent Sabatini as principal accounting officer.
Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled ...
Dupixent showed a 31% reduction in COPD exacerbations and improved lung function in a pooled analysis of BOREAS and NOTUS phase 3 studies, reinforcing its clinical benefit for uncontrolled COPD patients with type 2 inflammation.
Vir Biotechnology closes Sanofi licence deal for T-cell engagers
Vir Biotechnology has finalized an exclusive worldwide license agreement with Sanofi, gaining access to clinical-stage T-cell engagers (TCEs) and the PRO-XTEN masking platform for oncology and infectious disease. The deal includes three TCEs targeting distinct cancer markers and leverages the PRO-XTEN technology to enhance therapeutic index by selectively activating within the tumor microenvironment.
© Copyright 2025. All Rights Reserved by MedPath